logo

CAI

Caris Life Sciences·NASDAQ
--
--(--)
--
--(--)
9.73 / 10
Outperform

Financial evaluation reveals exceptional fundamentals, scoring 9.7/10. Key strengths include Cash-MV, PB-ROE, and Net cash flow from operating activities, while Diluted EPS YoY growth and Cash-UP present limitations. The PB-ROE factor is particularly strong at 7.4924, placing it in Group 4 with a 2/3 quality score. Overall judgment: excellent.

Fundamental(9.73)SentimentTechnical

Analysis Checks(3/10)

Revenue-MV
Value-1.39
Score0/3
Weight-73.00%
1M Return-4.76%
Net cash flow from operating activities per share (YoY growth rate %)
Value15.62
Score0/3
Weight-43.94%
1M Return-3.00%
Profit-MV
Value0.47
Score1/3
Weight12.29%
1M Return0.63%
Net income-Revenue
Value-0.25
Score1/3
Weight15.17%
1M Return0.88%
PB-ROE
Value7.49
Score2/3
Weight51.72%
1M Return2.91%
Total profit (YoY growth rate %)
Value38.74
Score1/3
Weight19.13%
1M Return1.03%
Net cash flow from operating activities (YoY growth rate %)
Value118.60
Score3/3
Weight107.61%
1M Return5.29%
Cash-UP
Value1.67
Score1/3
Weight-33.26%
1M Return-2.34%
Diluted earnings per share (YoY growth rate %)
Value45.85
Score0/3
Weight-39.23%
1M Return-2.81%
Cash-MV
Value-1.14
Score2/3
Weight83.51%
1M Return4.35%
Is CAI fundamentally strong?
  • CAI scores 9.73/10 on fundamentals and holds a Discounted valuation at present. Backed by its -616.29% ROE, -28.81% net margin, -7.75 P/E ratio, 12.93 P/B ratio, and 0.00% earnings growth, these metrics solidify its Outperform investment rating.